Medical Developments International Limited (MDDVF) Shareholder/Analyst Call Transcript
Mark Fladrich
Welcome, everyone, to the 2026 Annual General Meeting of your company. My name is Mark Fladrich, and I’m honored to address this AGM for the first time as Chairman. I extend a very warm welcome to everyone in the room and online to our fifth hybrid AGM. We are now very familiar with this format. It lets us engage with a wide group of shareholders while keeping the benefits of a face-to-face discussion.
I would also like to acknowledge and welcome Anita James, who joins us at this AGM in her new capacity as Interim CEO. While Anita is no stranger to our AGM in her role as CFO, this is her first time attending in the role of Interim CEO. The Board is delighted to have appointed Anita as interim. She knows our business well, understands our financial position and capital priorities and has strong relationships across the company and with our external stakeholders. Her appointment gives continuity and maintains momentum in the execution of our strategy.
Anita’s appointment follows Brent MacGregor’s decision to step down and return to the U.S. On behalf of the Board, I’d like to thank Brent for his leadership over the last — the past 6 years. During his time with us, MDI became a more efficient and more focused business with clear results in growing Penthrox revenue, better margins and regulatory milestones. As a result, the business is well positioned. Our strategy is clear, and we have capable leadership, including Anita, in place to act on the opportunities ahead.